PFE Talzenna Combination Demonstrates High Effectiveness in Broader Prostate Cancer Applications

Pfizer Announces Promising Results for Talzenna and Xtandi Combination in Prostate Cancer Trial

Pfizer (PFE) has shared encouraging initial findings from a pivotal clinical trial assessing the effectiveness of Talzenna (talazoparib), an oral PARP inhibitor, used alongside Xtandi (enzalutamide), an ARP inhibitor. This treatment approach was tested in individuals with metastatic castration-sensitive prostate cancer (mCSPC) who have mutations in HRR genes, a group also referred to as metastatic hormone-sensitive prostate cancer patients.

Talzenna originally received approval in the United States, European Union, and other regions as a standalone therapy for adults with certain types of advanced or metastatic breast cancer. Subsequently, the combination of Talzenna and Xtandi was authorized by the FDA for adults with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC), and is also approved in the EU for adults with mCRPC who are not candidates for chemotherapy. This combination is now available in about 60 countries, though the specific indications differ by location. For HRR gene-mutated mCSPC, however, the Talzenna/Xtandi regimen remains under investigation.

The phase III TALAPRO-3 trial conducted by Pfizer enrolled 599 patients diagnosed with mCSPC. Participants had received up to three months of androgen deprivation therapy, either chemically or surgically, with or without an approved ARP inhibitor. Patients were randomly assigned to receive either Talzenna (0.5 mg daily) plus Xtandi (160 mg daily) or a placebo with Xtandi (160 mg daily).

Over the last six months, Pfizer's stock has climbed 14%, in contrast to a 13% decline in the broader pharmaceutical industry.

Image Source: Zacks Investment Research

Key Findings from the TALAPRO-3 Study

According to Pfizer, the TALAPRO-3 study achieved its main objective: the combination of Talzenna and Xtandi significantly improved radiographic progression-free survival compared to placebo plus Xtandi. The results exceeded the pre-set hazard ratio goal of 0.63, with the majority of patients showing no disease progression at the time of analysis. These benefits were observed across various patient subgroups, including those with both BRCA and non-BRCA HRR gene mutations.

During interim analysis, Pfizer also reported a notable trend toward better overall survival, which was a key secondary measure. Additional positive outcomes were seen in other secondary endpoints, such as overall response rate, duration of response, and time to prostate-specific antigen progression. The safety profile of the combination therapy was consistent with what is already known for each drug individually, and no unexpected safety issues were identified.

Pfizer highlighted that current therapies often leave patients with HRR gene-mutated mCSPC at risk for early disease advancement. The TALAPRO-3 data indicate that introducing Talzenna and Xtandi earlier in treatment may significantly delay disease progression, suggesting a meaningful advantage for this approach.

Prostate cancer is the second most frequently diagnosed cancer in men worldwide, with approximately 330,000 new cases projected in the United States by 2026. Despite recent progress, nearly half to two-thirds of mCSPC patients develop mCRPC within two years, and those with HRR gene mutations—found in about a quarter of metastatic cases—face worse outcomes and limited responses to standard treatments, highlighting a critical need for new options.

Pfizer is preparing to present the full results from the TALAPRO-3 trial at an upcoming medical conference and intends to engage with regulatory agencies globally to discuss possible approval pathways for the Talzenna/Xtandi combination in mCSPC.

Pfizer Inc. Price and Analyst Consensus

For more details, see the Pfizer Inc. price-consensus chart or view the latest Pfizer Inc. quote.

Pfizer’s Zacks Rank and Alternative Biotech Stocks

Currently, Pfizer holds a Zacks Rank #3 (Hold).

Investors seeking higher-ranked biotech stocks might consider:

• Catalyst Pharmaceuticals (CPRX) – Zacks Rank #1 (Strong Buy)
• ADMA Biologics (ADMA) – Zacks Rank #2 (Buy)
• Inovio Pharmaceuticals (INO) – Zacks Rank #2 (Buy)

Find the complete list of today’s Zacks #1 Rank stocks here.

Over the last two months, Catalyst Pharmaceuticals’ projected 2026 earnings per share rose from $2.55 to $2.82, and its stock price increased by 11.3% in the past six months. The company has outperformed earnings expectations in each of the last four quarters, with an average surprise of 35.19%.

ADMA Biologics’ 2026 EPS estimates have increased from $0.85 to $0.96 over the past 60 days, though its shares have declined by 6.3% in the same period. The company exceeded earnings estimates in one of the last three quarters, matched once, and missed once, with an average negative surprise of 1.79%.

Inovio Pharmaceuticals has seen its projected 2026 loss per share narrow from $1.26 to $1.12 over the last two months, but its stock has dropped by 33.8% in the past six months. Inovio beat earnings expectations in all four of the most recent quarters, with an average surprise of 57.94%.

Top Semiconductor Stock Opportunity

The surging demand for data is driving a new wave of growth in the digital sector. As data centers continue to expand and modernize, companies supplying the necessary hardware are poised to become industry leaders, much like NVIDIA.

One lesser-known semiconductor manufacturer is especially well-positioned to benefit from this trend, focusing on products that major players like NVIDIA do not produce. This company is just starting to gain attention, making it an intriguing prospect for investors.

Discover this stock now for free >>

For the latest stock recommendations from Zacks Investment Research, you can download the report "7 Best Stocks for the Next 30 Days." Click here to access the free report.

Pfizer Inc. (PFE): Free Stock Analysis Report

Catalyst Pharmaceuticals, Inc. (CPRX): Free Stock Analysis Report

Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report

ADMA Biologics Inc (ADMA): Free Stock Analysis Report

This article was first published by Zacks Investment Research.

Zacks Investment Research